RankAlpha logo
Back to Rankings

MBRX

Moleculin BiotechF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The preliminary MIRACLE remission signal is confirmed in the larger Part A dataset, enabling dose selection and further development. These are scenario assumptions, not established outcomes.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -18.1.
What can break
Nasdaq issued a delisting determination; continued listing depends on the hearing process and renewed compliance. [#SEC-8K-2026-09-18]
Momentum
67
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.30 · Bull $0.75 · Bear $0.08Analysis 2026-10-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-26

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $240.00
Why
Momentum67 · Δ7d -
Value41 · Δ7d -18.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta -18.1.

Contradictions & invalidation

  • • Nasdaq issued a delisting determination; continued listing depends on the hearing process and renewed compliance. [#SEC-8K-2026-09-18]
  • • Shareholders approved adding 3,861,894 shares to the 2024 equity plan; authorization is not the same as immediate issuance. [#8-K-2026-10-09] SEC filing
  • • The larger dataset fails to confirm the preliminary signal, while listing uncertainty and a funding horizon only into first-quarter 2027 constrain financing options.

Catalyst clock

2026-12-31

Nasdaq listing decision

Lead driver: Value · See fundamentals
Momentum
67
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendSoftening
Δ7d
-18.1
Δ21d
-0.4
Sentiment
0
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 67.2 / Value 40.6 / Sentiment 0.0

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-16. Scenario method

B+
Bull case
20%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$0.30
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.08
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$7.44M
Beta
1.64
Shares Out
1.05M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.77
Rev YoY
-
EPS YoY
-95.1%
Gross Margin
-
Op Margin
-
Net Debt
-$8.52M
Current Ratio
0.94
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data